Cargando…

Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications

Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Pei, Li, Guangqing, Wu, Lu, Huang, Minger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875293/
https://www.ncbi.nlm.nih.gov/pubmed/36713431
http://dx.doi.org/10.3389/fimmu.2022.1065379
_version_ 1784877934302986240
author Du, Pei
Li, Guangqing
Wu, Lu
Huang, Minger
author_facet Du, Pei
Li, Guangqing
Wu, Lu
Huang, Minger
author_sort Du, Pei
collection PubMed
description Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future.
format Online
Article
Text
id pubmed-9875293
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98752932023-01-26 Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications Du, Pei Li, Guangqing Wu, Lu Huang, Minger Front Immunol Immunology Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future. Frontiers Media S.A. 2023-01-11 /pmc/articles/PMC9875293/ /pubmed/36713431 http://dx.doi.org/10.3389/fimmu.2022.1065379 Text en Copyright © 2023 Du, Li, Wu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Du, Pei
Li, Guangqing
Wu, Lu
Huang, Minger
Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
title Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
title_full Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
title_fullStr Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
title_full_unstemmed Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
title_short Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
title_sort perspectives of ercc1 in early-stage and advanced cervical cancer: from experiments to clinical applications
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875293/
https://www.ncbi.nlm.nih.gov/pubmed/36713431
http://dx.doi.org/10.3389/fimmu.2022.1065379
work_keys_str_mv AT dupei perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications
AT liguangqing perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications
AT wulu perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications
AT huangminger perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications